Argenx Shares Soar on Clinical Trial Hype as $380M Volume Surge Propels It to 229th in Active Stock Rankings

On August 25, 2025, argenx (ARGX) surged 2.62% to close at $XX.XX, with a daily trading volume of $380 million—a 153.95% increase from the prior day—ranking it 229th among active stocks. The biopharma company’s shares saw renewed institutional interest following updated clinical trial data for its monoclonal antibody candidate, which demonstrated improved efficacy metrics in Phase III trials for autoimmune disorders.

Analysts noted that the volume spike aligned with a broader biotech sector rebound, though argenx outperformed peers due to its focused pipeline updates. Short-term traders capitalized on the momentum, with high-frequency trading activity accounting for nearly 40% of total shares traded. The stock’s 20-day relative volume of 2.1x suggested temporary speculative positioning ahead of an October FDA advisory panel meeting on its lead asset.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. The strategy's Sharpe ratio was 0.79, indicating good risk-adjusted returns. The highest daily return was 4.95%, and the lowest was -4.47%. This backtest shows the strategy's ability to capture short-term momentum while facing volatility in the stock market.